Evogene Ltd Share Price Other OTC
Equities
IL0011050551
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
05-23 | Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M | MT |
05-23 | Evogene Ltd. Provides Revenue Guidance for the Year 2024 | CI |
Sales 2024 * | 17M 1.34B | Sales 2025 * | 31.5M 2.49B | Capitalization | 31.44M 2.48B |
---|---|---|---|---|---|
Net income 2024 * | -20M -1.58B | Net income 2025 * | -17M -1.34B | EV / Sales 2024 * | 1.85 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.34% |
Latest transcript on Evogene Ltd
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 31/12/01 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 31/03/22 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/12/04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 16/11/21 |
Sarit Firon
CHM | Chairman | 58 | 10/08/16 |
Leon Recanati
BRD | Director/Board Member | 76 | 30/04/05 |
1st Jan change | Capi. | |
---|---|---|
+38.36% | 52.73B | |
+38.87% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |